Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.
Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.